• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥密克戎 BA.2.87.1 对血清中和的敏感性高于 EG.5.1 和 JN.1。

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.

机构信息

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Pandemic Research Alliance unit at the Wu Family Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

出版信息

Emerg Microbes Infect. 2024 Dec;13(1):2359004. doi: 10.1080/22221751.2024.2359004. Epub 2024 May 31.

DOI:10.1080/22221751.2024.2359004
PMID:38779718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11146261/
Abstract

As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1. Compared with other Omicron subvariants, including EG.5.1 and the current predominant JN.1, BA.2.87.1 exhibits less immune evasion, reduced viral receptor engagement, and comparable infectivity in Calu-3 lung cells. Intriguingly, two large deletions (Δ15-26 and Δ136-146) in the N-terminal domain (NTD) of the spike protein facilitate subtly increased antibody evasion but significantly diminish viral infectivity. Collectively, our data support the announcement by the USA CDC that the public health risk posed by BA.2.87.1 appears to be low.

摘要

随着 SARS-CoV-2 的持续传播和变异,追踪病毒的进化轨迹并了解其突变的功能后果仍然至关重要。在这里,我们描述了高度变异的 SARS-CoV-2 Omicron 亚变体 BA.2.87.1 的抗体逃逸、ACE2 受体结合和病毒感染力。与其他 Omicron 亚变体(包括 EG.5.1 和当前主要的 JN.1)相比,BA.2.87.1 表现出较低的免疫逃逸、降低的病毒受体结合和在 Calu-3 肺细胞中相当的感染力。有趣的是,刺突蛋白(spike protein)N 端结构域(NTD)中的两个大缺失(Δ15-26 和 Δ136-146)促进了微妙的抗体逃逸增加,但显著降低了病毒感染力。总的来说,我们的数据支持美国疾病控制与预防中心(USA CDC)的声明,即 BA.2.87.1 带来的公共卫生风险似乎较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2985/11146261/7b18769badef/TEMI_A_2359004_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2985/11146261/7b18769badef/TEMI_A_2359004_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2985/11146261/7b18769badef/TEMI_A_2359004_F0001_OC.jpg

相似文献

1
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.奥密克戎 BA.2.87.1 对血清中和的敏感性高于 EG.5.1 和 JN.1。
Emerg Microbes Infect. 2024 Dec;13(1):2359004. doi: 10.1080/22221751.2024.2359004. Epub 2024 May 31.
2
Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.SARS-CoV-2 BA.2.86 和 JN.1 亚变种的进化和抗体逃逸的结构基础。
Nat Commun. 2024 Sep 4;15(1):7715. doi: 10.1038/s41467-024-51973-8.
3
AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.AlphaFold2 对 SARS-CoV-2 刺突奥密克戎 JN.1、KP.2 和 KP.3 变体构象集合的建模和分子动力学模拟:结合能突变分析揭示 ACE2 亲和力的上位驱动因素和抗体耐药性逃逸热点。
Viruses. 2024 Sep 13;16(9):1458. doi: 10.3390/v16091458.
4
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.复发性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突突变赋予选定的JN.1亚谱系生长优势。
Emerg Microbes Infect. 2024 Dec;13(1):2402880. doi: 10.1080/22221751.2024.2402880. Epub 2024 Sep 16.
5
Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.SARS-CoV-2 BA.2.87.1 和 JN.1 变体在免疫逃逸、抗原性和细胞间融合方面的独特模式。
mBio. 2024 May 8;15(5):e0075124. doi: 10.1128/mbio.00751-24. Epub 2024 Apr 9.
6
Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.最近流行的 SARS-CoV-2 奥密克戎 BA.2.86、JN.1、EG.5、EG.5.1 和 HV.1 亚变体的刺突结构、受体结合和免疫逃逸。
Structure. 2024 Aug 8;32(8):1055-1067.e6. doi: 10.1016/j.str.2024.06.012. Epub 2024 Jul 15.
7
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.刺突蛋白结构特征、决定病毒进入宿主细胞的物种特异性血管紧张素转换酶 2 残基,以及奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 变异株的抗体中和逃逸。
J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.
8
Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.针对 Spike N 端结构域 N1/N2 环的奥密克戎特异性超强 SARS-CoV-2 中和抗体。
Emerg Microbes Infect. 2024 Dec;13(1):2412990. doi: 10.1080/22221751.2024.2412990. Epub 2024 Oct 28.
9
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.SARS-CoV-2 刺突变异株的中和抗性主要由协同受体结合域取代介导。
Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13.
10
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.

引用本文的文献

1
Multiscale Modeling and Dynamic Mutational Profiling of Binding Energetics and Immune Escape for Class I Antibodies with SARS-CoV-2 Spike Protein: Dissecting Mechanisms of High Resistance to Viral Escape Against Emerging Variants.针对与SARS-CoV-2刺突蛋白结合的I类抗体的结合能和免疫逃逸的多尺度建模与动态突变分析:剖析对病毒逃逸针对新出现变体的高抗性机制。
Viruses. 2025 Jul 23;17(8):1029. doi: 10.3390/v17081029.
2
Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results.基于抗武汉-胡-1受体结合域的商业免疫分析结果估算SARS-CoV-2奥密克戎XBB.1.5刺突定向功能性抗体水平
J Med Virol. 2025 Jan;97(1):e70130. doi: 10.1002/jmv.70130.
3

本文引用的文献

1
Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage.严重急性呼吸综合征冠状病毒2型BA.2.87.1谱系的病毒学特征
Vaccines (Basel). 2024 May 1;12(5):487. doi: 10.3390/vaccines12050487.
2
Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies.三价XBB疫苗诱导的抗体对包括JN.1和BA.2.87.1在内的SARS-CoV-2变体具有强大的中和作用。
Signal Transduct Target Ther. 2024 May 9;9(1):123. doi: 10.1038/s41392-024-01849-6.
3
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
COVID-19 Serum Drives Spike-Mediated SARS-CoV-2 Variation.
COVID-19 血清推动了 Spike 介导的 SARS-CoV-2 变异。
Viruses. 2024 May 11;16(5):763. doi: 10.3390/v16050763.
4
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.新型冠状病毒跳跃变异株BA.2.87.1的抗原性评估
Emerg Microbes Infect. 2024 Dec;13(1):2343909. doi: 10.1080/22221751.2024.2343909. Epub 2024 May 2.
新型冠状病毒跳跃变异株BA.2.87.1的抗原性评估
Emerg Microbes Infect. 2024 Dec;13(1):2343909. doi: 10.1080/22221751.2024.2343909. Epub 2024 May 2.
4
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.SARS-CoV-2 奥密克戎变异株 BA.2.87.1 的中和作用。
Vaccine. 2024 Apr 2;42(9):2117-2121. doi: 10.1016/j.vaccine.2024.03.007. Epub 2024 Mar 7.
5
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.XBB.1.5 单价 mRNA 疫苗加强针可诱导针对 XBB 亚谱系和 JN.1 的强大中和抗体。
Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. doi: 10.1016/j.chom.2024.01.014. Epub 2024 Feb 19.
6
GISAID's Role in Pandemic Response.全球流感共享数据库(GISAID)在大流行应对中的作用。
China CDC Wkly. 2021 Dec 3;3(49):1049-1051. doi: 10.46234/ccdcw2021.255.